{"filings":[{"id":70561,"accession_number":"0001171843-26-003381","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-05-13T21:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.","Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.","Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).","TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.","Luxeptinib license rights returned to CGI; program winding down."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99395,"accession_number":"0001171843-26-002877","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose delays closing of Hanmi arrangement; targets May 2026 for completion","event_type":"m_and_a","confidence":"high","bullets":["Closing delayed as Korean regulatory approvals remain in progress; parties do not anticipate prevention.","Hanmi will acquire all outstanding Aptose shares at C$2.41 per share, a 28% premium to C$1.88 VWAP.","Transaction originally announced Nov 19, 2025; closing expected in May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115374,"accession_number":"0001193125-26-134870","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aptose shareholders approve continuance to Alberta and Hanmi acquisition arrangement","event_type":"m_and_a","confidence":"high","bullets":["Continuance from CBCA to Alberta approved with 92.42% votes in favor.","Arrangement with Hanmi (HS North America Ltd.) approved with 84.87% votes in favor.","Arrangement announced Nov 19, 2025; Hanmi to acquire all outstanding shares not already owned.","Special meeting held March 31, 2026; all items passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115373,"accession_number":"0001171843-26-002103","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).","84.87% of non-Hanmi shares voted for the arrangement; Alberta court issued final order; closing expected by end of April 2026.","FY2025 net loss $25.5M (flat vs $25.4M); cash $4.1M as of Dec 31, 2025; company notes insufficient cash to fund operations; relies on Hanmi advances.","TUS+VEN+AZA triplet in newly diagnosed AML showed 90% CR/CRh, 78% MRD negativity by central flow; no dose-limiting toxicities.","Hanmi provided over US$41M in debt facilities over past 18 months to support Aptose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115372,"accession_number":"0001193125-26-119951","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Aptose amends CEO Rice's employment agreement; confirms no deferred compensation owed","event_type":"other_material","confidence":"high","bullets":["First Amendment to CEO William Rice's employment agreement confirms no deferred compensation plan was ever established.","Rice acknowledges sole responsibility for all individual taxes, penalties, and interest on benefits paid under agreement.","Amendment clarifies that references to 'Deferred Compensation Plan' in prior agreements are disregarded.","No change in Rice's role; continues as Chairman, President, and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115371,"accession_number":"0001171843-26-001837","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glass Lewis backs Aptose's plan for Hanmi acquisition; vote deadline March 27","event_type":"m_and_a","confidence":"high","bullets":["Glass Lewis recommends shareholders vote FOR the arrangement with Hanmi and the continuance to ABCA.","Proxy voting deadline is 11:00 a.m. EST on Friday, March 27, 2026.","Special meeting reconvened for March 31, 2026, after SEC comments on the transaction statement.","Board and Special Transaction Committee unanimously recommend voting FOR the arrangement.","Deal is subject to court approval and TSX approval; Sodali & Co assisting with proxy solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.62,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115370,"accession_number":"0001171843-26-001777","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ISS recommends Aptose shareholders vote FOR Hanmi arrangement at C$2.41/share","event_type":"m_and_a","confidence":"high","bullets":["ISS recommends voting FOR the arrangement with Hanmi Pharmaceutical and the continuance to ABCA.","Shareholders to receive C$2.41 per share cash, a 28% premium over the 30-day VWAP of C$1.88.","Special meeting reconvened to March 31, 2026; proxy deadline is March 27, 2026 at 11:00 AM ET.","Board of directors unanimously recommends approval of the arrangement resolution.","Completion subject to court approval, TSX approval, and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115369,"accession_number":"0001193125-26-064847","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan","event_type":"m_and_a","confidence":"high","bullets":["Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.","Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.","Facility funds clinical development of Tuspetinib for AML triplet therapy.","Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.","Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131780,"accession_number":"0001171843-25-008045","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose reschedules special meeting for Hanmi acquisition pending SEC clearance","event_type":"m_and_a","confidence":"medium","bullets":["Special meeting moved from Jan 16, 2026 to later date in January 2026.","Rescheduling due to awaiting final SEC clearance of proxy statement.","Unanimous board recommendation to vote for the continuance and arrangement.","Record date remains Dec 12, 2025; no changes to matters to be voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131779,"accession_number":"0001171843-25-007795","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML","event_type":"other_material","confidence":"high","bullets":["90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.","78% of responders achieved MRD negativity by central flow cytometry.","No dose-limiting toxicities or drug-related deaths; febrile neutropenia in 2 subjects (16.7%).","Responses seen in FLT3-WT, TP53/complex karyotype, RAS, and MDS-related mutations.","Preliminary data at 160 mg cohort show early blast clearance and MRD negativity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131778,"accession_number":"0001193125-25-294108","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash","event_type":"m_and_a","confidence":"high","bullets":["Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.","Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.","Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.","Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.","Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131777,"accession_number":"0001171843-25-007415","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP","event_type":"m_and_a","confidence":"high","bullets":["Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.","Transaction requires approval of 2/3 of votes, plus minority approval; special meeting by Jan 16, 2026.","Formal valuation by Locust Walk: fair market value range of C$1.00 to C$5.23 per share.","Aptose will be delisted from TSX and cease Canadian reporting obligations after closing.","Officers and directors have entered voting support agreements in favor of the arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131776,"accession_number":"0001171843-25-007293","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses","event_type":"earnings","confidence":"high","bullets":["Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.","Cash and equivalents $1.6M as of Sep 30, 2025; company states insufficient cash to fund operations, relying on Hanmi advances.","TUS+VEN+AZA triplet: 6/6 (100%) achieved CR/CRh at 80/120 mg TUS doses, exceeding 66% expected from VEN+AZA alone; overall 9/10 (90%) CR/CRh.","Dose escalation to 160 mg TUS underway; updated data to be presented at ASH December 2025.","Shareholders' deficit of $19.5M; company actively pursuing financing and cost reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131775,"accession_number":"0001171843-25-006885","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose TUSCANY abstract accepted for ASH 2025 poster session","event_type":"other_material","confidence":"high","bullets":["Abstract #1645 from TUSCANY trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML selected for ASH 2025 poster presentation.","Poster session December 6, 2025, 5:30-7:30 PM in Orlando, FL.","Abstract available now; additional data to be presented in the poster.","Aptose developing tuspetinib-based triple therapy for patients ineligible for induction chemo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131774,"accession_number":"0001171843-25-006472","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose tuspetinib combo achieves 100% CR/CRh at higher doses in newly diagnosed AML trial","event_type":"other_material","confidence":"high","bullets":["TUS+VEN+AZA achieved 100% CR/CRh (6/6) at 80mg and 120mg doses, exceeding 66% expected from VEN+AZA alone.","CR/CRh in 7/8 (88%) FLT3 wildtype AML; responses across TP53, RAS, FLT3-ITD mutations.","No dose-limiting toxicities, QTc prolongation, differentiation syndrome, or prolonged myelosuppression seen.","Dosing at 160mg TUS level now ongoing; trial enrolling 18-24 patients by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148376,"accession_number":"0001171843-25-005992","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study","event_type":"debt","confidence":"high","bullets":["Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.","Final $1.4M advance received under prior June 2025 facility, totaling $8.5M from that agreement.","Loan is a related-party transaction; Aptose relies on financial hardship exemption from formal valuation and minority approval.","Proceeds fund TUSCANY Phase 1/2 trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML patients.","Early data showed 9/10 patients responded; 100% CR/CRh at 80mg and 120mg cohorts across adverse mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148375,"accession_number":"0001193125-25-189846","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Aptose Biosciences appoints EY as independent auditor, replacing KPMG","event_type":"other_material","confidence":"high","bullets":["KPMG informed company it would not stand for re-appointment for 2025 annual audit.","Board approved EY as independent auditor; shareholders voted approval at reconvened meeting on August 22, 2025.","No disagreements or reportable events between company and KPMG during past two fiscal years.","KPMG letter agreeing with disclosures attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148374,"accession_number":"0001193125-25-189841","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aptose Biosciences enters retention agreements with CEO, CFO, and CMO totaling ~$698K upon change of control","event_type":"other","confidence":"high","bullets":["CEO William Rice receives $331,496 retention grant; CFO Fletcher Payne $167,059; CMO Rafael Bejar $199,947.","Payments due within 5 days of a change of control closing.","Grants forfeited if executive is not actively employed at change of control closing.","Aims to reward, retain, and incentivize leadership team for long-term shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148373,"accession_number":"0001171843-25-005581","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Aptose Biosciences appoints EY as auditor and receives additional $1.5M from Hanmi for tuspetinib","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 96.95% in favor of appointing Ernst & Young LLP as independent registered public accounting firm.","Received an additional US$1.5M advance from Hanmi Pharmaceutical under the existing US$8.5M loan facility.","Total advances under the loan facility now US$7.1M to support clinical development of tuspetinib.","Funds will be used to continue development of tuspetinib-based triple drug frontline therapy for newly diagnosed AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148372,"accession_number":"0001171843-25-005555","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose appoints EY as auditor, receives $1.5M advance from Hanmi for AML drug","event_type":"other_material","confidence":"medium","bullets":["Shareholders voted to appoint Ernst & Young as independent auditor at reconvened annual meeting.","Received additional $1.5M advance from Hanmi under $8.5M loan facility, total drawn now $7.1M.","Funds support continued clinical development of tuspetinib-based triplet therapy for AML.","Aptose is a clinical-stage oncology company focused on front-line AML treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148371,"accession_number":"0001171843-25-005463","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial","event_type":"other_material","confidence":"high","bullets":["100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).","78% MRD-negativity among responders (7/9); 100% MRD-negativity in TP53, RAS, FLT3-ITD subgroups.","No dose-limiting toxicities or prolonged myelosuppression; enrollment advancing to 160 mg cohort.","Single non-responder was at 40 mg dose with subtherapeutic TUS exposure; all other patients remain on study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148370,"accession_number":"0001171843-25-005383","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg","event_type":"earnings","confidence":"high","bullets":["Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.","Cash and equivalents $1.3M as of June 30, 2025; company says cash insufficient to fund operations, relying on Hanmi loan of up to $8.5M.","Safety Review Committee approved dose escalation of tuspetinib to 160 mg in TUS+VEN+AZA TUSCANY trial; 120 mg cohort all patients remain on study.","All 10 enrolled subjects in TUSCANY triplet remain on treatment; CRs achieved at 40 mg and 80 mg doses across diverse AML mutations.","Selected EY as new auditor; annual meeting reconvened for August 22, 2025 to vote on appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148369,"accession_number":"0001171843-25-005124","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi","event_type":"other_material","confidence":"high","bullets":["CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.","TUS+VEN+AZA triplet achieved CRs and MRD negativity in patients with adverse TP53 and FLT3-ITD mutations.","Aptose received $1.1M advance from Hanmi under $8.5M loan, bringing total advances to $5.6M.","Enrollment open for 160 mg cohort; all 120 mg patients remain on study.","Trial anticipates enrolling 18-24 patients by late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148368,"accession_number":"0001171843-25-004474","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial","event_type":"debt","confidence":"high","bullets":["Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.","Funds directed to ongoing TUSCANY Phase 1/2 study of tuspetinib triplet therapy in newly diagnosed AML.","Tuspetinib combination with venetoclax/azacitidine showed safety and MRD negativity in early data.","Loan facility announced June 20, 2025; proceeds extend Aptose's cash runway for clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148367,"accession_number":"0001193125-25-154170","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Aptose defers interest payment on Hanmi loan to December 31, 2025","event_type":"debt","confidence":"high","bullets":["Interest for Dec 21, 2024–Mar 31, 2025, originally due June 27, 2025, deferred to Dec 31, 2025.","Interest for Mar 31–Jun 30, 2025 also deferred to Dec 31, 2025.","Interest Deferral Agreement signed June 24, 2025 between Aptose and Hanmi.","Aptose is a clinical-stage precision oncology company developing tuspetinib for AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148366,"accession_number":"0001171843-25-004249","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose Biosciences upgraded to OTCQB market; begins trading under APTOF","event_type":"other_material","confidence":"high","bullets":["Company upgraded to OTCQB Market, effective July 1, 2025.","New ticker symbol APTOF on OTCQB.","Continues trading on Toronto Stock Exchange under symbol APS.","OTCQB requires current reporting and annual management certification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167156,"accession_number":"0001171843-25-004118","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development","event_type":"debt","confidence":"high","bullets":["Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.","Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.","Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.","Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.","Previous 2024 facility agreement also exists; new loan is separate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167155,"accession_number":"0001171843-25-003985","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development","event_type":"debt","confidence":"high","bullets":["Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.","Loan is a related-party transaction; Aptose relies on 'financial hardship' exemption from formal valuation and minority shareholder approval.","Tuspetinib is an oral agent targeting SYK, FLT3, KIT, JAK1/2, RSK2; ongoing TUSCANY Phase 1/2 trial in newly diagnosed AML with azacitidine and venetoclax.","Early data from first two dose cohorts showed safety, CRs, and MRD negativity across diverse mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167154,"accession_number":"0001171843-25-003962","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Board director Carol Ashe resigns from Aptose Biosciences, effective immediately","event_type":"leadership","confidence":"high","bullets":["Carol Ashe resigned from the Board of Aptose Biosciences effective June 16, 2025.","Resignation not due to any disagreement with the company's operations, policies, or practices.","No replacement director named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167153,"accession_number":"0001171843-25-003935","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose obtains CEO cash advance; warns of possible insolvency without additional funding in coming days","event_type":"other_material","confidence":"high","bullets":["CEO William Rice provides non-interest bearing, unsecured short-term cash advance to support payroll and obligations.","Company warns it may not have sufficient resources and could enter insolvency proceedings without additional funding in coming days.","Director Carol Ashe resigned effective June 16, 2025.","Advance is a related-party transaction exempt from formal valuation and minority approval under MI 61-101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167152,"accession_number":"0001171843-25-003854","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose reports safety, CRs, MRD negativity in TUSCANY triplet for newly diagnosed AML","event_type":"other_material","confidence":"high","bullets":["Ten newly diagnosed AML patients dosed in TUS+VEN+AZA triplet at 40, 80, 120 mg TUS; no DLTs observed.","At 40 mg, 3 of 4 patients achieved CRs and MRD negativity, including FLT3-ITD, FLT3-WT, and TP53/CK.","At 80 mg, all 3 patients achieved composite CRs (CR/CRi); one TP53-mutated/CK patient had early CRi.","No treatment-related deaths; all 10 subjects remain alive; no prolonged myelosuppression or QT prolongation.","Data presented at EHA 2025; TUS+VEN+AZA well-tolerated with standard of care dosing; enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167151,"accession_number":"0001171843-25-003505","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Aptose shareholders approve reverse stock split and stock plan amendment; meeting adjourned for auditor search","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees re-elected with ≥97.69% votes for.","Shareholders approved amendment to 2021 stock plan increasing reserved shares by 458,126.","Reverse stock split authorized (1:2 to 1:20) at board discretion; ratio and date TBD.","Meeting adjourned to allow search for successor auditor to KPMG LLP; new meeting date to be set."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167150,"accession_number":"0001171843-25-003326","cik":882361,"company_name":"Aptose Biosciences Inc.","ticker":"APTOF","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aptose doses first patient at 120 mg tuspetinib in TUSCANY triplet trial after positive safety review","event_type":"other_material","confidence":"high","bullets":["CSRC cleared escalation to 120 mg TUS based on safety from 40 mg and 80 mg cohorts.","First patient dosed at 120 mg as part of TUS+VEN+AZA triplet frontline therapy for AML.","No prolonged myelosuppression or dose-limiting toxicities reported in first two cohorts.","Complete remissions and MRD negativity observed across diverse AML mutations.","Updated data to be presented at EHA 2025 congress (June 12-15) in Milan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}